Search

Your search keyword '"Minamisawa, Masatoshi"' showing total 280 results
Start Over Author "Minamisawa, Masatoshi"
280 results on '"Minamisawa, Masatoshi"'

1. Impact of hyper-polypharmacy due to non-cardiovascular medications on long-term clinical outcomes following endovascular treatment for lower limb artery disease: A sub-analysis of the I-PAD Nagano registry

Author

Kato, Tamon, Minamisawa, Masatoshi, Miura, Takashi, Kanai, Masafumi, Oyama, Yushi, Hashizume, Naoto, Yokota, Daisuke, Taki, Minami, Senda, Keisuke, Nishikawa, Ken, Wakabayashi, Tadamasa, Fujimori, Koki, Karube, Kenichi, Sakai, Takahiro, Inoue, Minami, Yoda, Hidetsugu, Sunohara, Daisuke, Okina, Yoshiteru, Nomi, Hidetomo, Kanzaki, Yusuke, Machida, Keisuke, Kashiwagi, Daisuke, Ueki, Yasushi, Saigusa, Tatsuya, Ebisawa, Soichiro, Okada, Ayako, Motoki, Hirohiko, and Kuwahara, Koichiro

Published
2024
Full Text
View/download PDF

2. Association between complete revascularization of the coronary artery and clinical outcomes in peripheral artery disease: a sub-analysis of the I-PAD Nagano registry

Author

Kato, Tamon, Ueki, Yasushi, Minamisawa, Masatoshi, Miura, Takashi, Oyama, Yushi, Hashizume, Naoto, Yokota, Daisuke, Taki, Minami, Senda, Keisuke, Okina, Yoshiteru, Wakabayashi, Tadamasa, Fujimori, Koki, Karube, Kenichi, Sakai, Takahiro, Nomi, Hidetomo, Yui, Hisanori, Kanzaki, Yusuke, Machida, Keisuke, Maruyama, Shusaku, Nagae, Ayumu, Saigusa, Tatsuya, Ebisawa, Soichiro, Okada, Ayako, Motoki, Hirohiko, and Kuwahara, Koichiro

Published
2023
Full Text
View/download PDF

6. Treatment time limit for successful weaning from veno‐arterial extracorporeal membrane oxygenation in cardiogenic shock.

Author

Suzuki, Sho, Ito, Kii, Teraoka, Nami, Okuma, Yukari, Kimura, Kazuhiro, Minamisawa, Masatoshi, Ebisawa, Soichiro, Motoki, Hirohiko, Imamura, Hiroshi, Seto, Tatsuichiro, and Kuwahara, Koichiro

Subjects
HEART valve diseases, MYOCARDIAL infarction, CARDIOGENIC shock, ARTIFICIAL blood circulation, EXTRACORPOREAL membrane oxygenation, INTRA-aortic balloon counterpulsation
Abstract

Aims: Knowing the upper time limit for successful weaning from temporary mechanical circulatory support in cardiogenic shock will help with decision‐making regarding advanced heart failure (HF) therapy or considering withdrawal of care. The aim of this study was to investigate the association between the support duration and successful weaning from veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) in patients with cardiogenic shock. Methods and results: A retrospective single‐centre cohort study was conducted between January 2013 and June 2023. It included 100 consecutive patients with cardiogenic shock who were treated with VA‐ECMO. Patients with out‐of‐hospital cardiac arrest were excluded. The primary outcome was successful weaning from VA‐ECMO (i.e., VA‐ECMO decannulation and survival to discharge). The association between the length of support duration and the weaning success rate was analysed. Patients were divided into three groups according to ECMO support duration: Group A (≤7 days), Group B (8–14 days), and Group C (≥15 days). Multivariable logistic regression analysis was used to evaluate the impact of the length of support duration on successful weaning of VA‐ECMO. The median age was 67 years, and 73% of study participants were male. The underlying aetiologies of cardiogenic shock were as follows: acute myocardial infarction, 50; fulminant myocarditis, 19; cardiomyopathy, 15; valvular heart disease, 8; and other, 8. Seventy‐five patients (75%) were attempted to wean VA‐ECMO, and 67 moved on to decannulation. In total, 43 (43%) patients were successfully weaned from VA‐ECMO. The median length of ECMO support duration was 8 [3–15] days. Compared with those who underwent successful ECMO decannulation, those who did not had a significantly longer support duration of VA‐ECMO (5 [3–9] days vs. 12 [3–22] days, P = 0.004). The weaning success rate was significantly higher in patients with short support duration; 58% (29/50), 40% (10/25), 16% (4/25) in Groups A, B, and C, respectively (P = 0.002). Overall, none of the patients supported for over 24 days (0/11) were successfully weaned from VA‐ECMO. On multivariable logistic regression analysis, the length of support duration was independently associated with successful weaning after adjusting for age, sex, underlying aetiology, and left ventricular ejection fraction (odds ratio, 0.813 [per 3 days]; 95% confidence interval, 0.679–0.914; P = 0.025). Conclusions: Long support duration of VA‐ECMO was significantly associated with a low rate of successful weaning in patients with cardiogenic shock. Patients who require VA‐ECMO for over 1 week should start considering advanced HF therapy or withdrawal of care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.

Author

Kato, Takao, Ines, Monica, Minamisawa, Masatoshi, Benjumea, Darrin, Keohane, Denis, Alvir, Jose, Kim, Ruth, Chen, Yong, Peixoto, Telma, Kent, Matthew, Wogen, Jenifer, Ishii, Tomonori, Crowley, Aaron, Sugino, Toshiya, and Izumiya, Yasuhiro

Subjects
PATIENT compliance, ANGIOTENSIN-receptor blockers, HEART failure patients, HEART diseases, DATABASES, HEART failure
Abstract

Aims: This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) treated with tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database. Methods and results: This study was a non‐interventional, retrospective cohort study of adult (≥18 years old) patients in the Japanese MDV claims database diagnosed with ATTR‐CM and with at least two tafamidis prescriptions of dose strength 4 × 20 mg/day between 1 March 2019 and 31 August 2021. The date of the first prescription was defined as the index date, with follow‐up time defined as the time between the first and last prescription plus the days' supply from the last refill. Baseline characteristics were assessed during a 12 month pre‐index period. Adherence was measured using two metrics: (i) the modified medication possession ratio (mMPR), calculated by taking the sum of days supplied for all fills within the follow‐up period, divided by the number of days of follow‐up, and reported as a percentage, with patients classified as adherent with an mMPR of ≥80%, and (ii) the proportion of days covered (PDC), calculated by taking the total number of days' supply dispensed during the follow‐up period divided by the number of days of follow‐up, adjusting for any days' supply overlap. A total of 210 patients were identified; the mean (standard deviation) age of the cohort was 77 (5.9) years, and the majority (89%) were male. The most common baseline cardiovascular comorbidities were heart failure (85%), ischaemic heart disease (66%), hypertensive diseases (49%), and diabetes (35%); 75% of patients received heart failure medications in the 12 months prior to index, with the most common being beta‐blockers (49%), diuretics (48%), angiotensin receptor blockers (30%), angiotensin‐converting enzyme inhibitors (22%), and sodium–glucose cotransporter‐2 inhibitors (8.1%). Over an average 14 month follow‐up, mean mMPR was 96% with a median of 100% [inter‐quartile range (IQR): 97–101%]; 93% of patients were adherent (defined as an mMPR ≥ 80%). In the same follow‐up period, mean PDC was 93.6% with a median of 99% (IQR: 93–100%). Persistence was high with 78% of patients having a 0 day gap between prescription refills. Conclusions: This study found high adherence rates to tafamidis in this real‐world Japanese patient population. Adherence rates in this study were similar to those reported by the tafamidis clinical trial and a previously published US commercial claims adherence analysis. Further studies should be conducted to assess the impact of real‐world adherence on real‐world outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study

Author

Minamisawa, Masatoshi, primary, Inciardi, Riccardo M., additional, Claggett, Brian, additional, Cikes, Maja, additional, Liu, Li, additional, Prasad, Narayana, additional, Biering‐Sørensen, Tor, additional, Lam, Carolyn S.P., additional, Shah, Sanjiv J., additional, Zile, Michael R., additional, O'Meara, Eileen, additional, Redfield, Margaret M., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Shah, Amil M., additional

Published
2024
Full Text
View/download PDF

17. Prognostic Impact of Hyperpolypharmacy Due to Noncardiovascular Medications in Patients After Acute Decompensated Heart Failure ― Insights From the Clue of Risk Stratification in the Elderly Patients With Heart Failure (CURE-HF) Registry ―

Author

Kanai, Masafumi, primary, Minamisawa, Masatoshi, additional, Motoki, Hirohiko, additional, Seko, Yuta, additional, Kimura, Kazuhiro, additional, Okano, Takahiro, additional, Ueki, Yasushi, additional, Yoshie, Koji, additional, Kato, Tamon, additional, Saigusa, Tatsuya, additional, Ebisawa, Soichiro, additional, Okada, Ayako, additional, Ozasa, Neiko, additional, Kato, Takao, additional, and Kuwahara, Koichiro, additional

Published
2023
Full Text
View/download PDF

18. Clinical Profile and Prognosis of Dementia in Patients With Acute Decompensated Heart Failure ― From the CURE-HF Registry ―

Author

Machida, Keisuke, primary, Minamisawa, Masatoshi, additional, Motoki, Hirohiko, additional, Teramoto, Kanako, additional, Okuma, Yukari, additional, Kanai, Masafumi, additional, Kimura, Kazuhiro, additional, Okano, Takahiro, additional, Ueki, Yasushi, additional, Yoshie, Koji, additional, Kato, Tamon, additional, Saigusa, Tatsuya, additional, Ebisawa, Soichiro, additional, Okada, Ayako, additional, and Kuwahara, Koichiro, additional

Published
2023
Full Text
View/download PDF

20. Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction

Author

Biering-Sorensen, Tor, Cikes, Maja, Lassen, Mats C. H., Claggett, Brian, Minamisawa, Masatoshi, Santos, Angela B. S., Pieske-Kraigher, Elisabeth, Shah, Amil M., Zile, Michael R., McMurray, John J., Solomon, Scott D., Cheng, Susan, Biering-Sorensen, Tor, Cikes, Maja, Lassen, Mats C. H., Claggett, Brian, Minamisawa, Masatoshi, Santos, Angela B. S., Pieske-Kraigher, Elisabeth, Shah, Amil M., Zile, Michael R., McMurray, John J., Solomon, Scott D., and Cheng, Susan

Abstract

Aims Hypertensive heart disease (HHD) is recognized as a key clinical precursor to heart failure with preserved ejection fraction (HFPEF). However, pathophysiological transition from HHD to HFPEF is not well understood. We sought determine whether regional differences in impaired myocardial function may underlie the greater mechanical dysfunction seen in HFPEF compared to HHD.Methods and results We used standardized echocardiography to assess regional myocardial deformation in a cohort of n = 327 adults with preserved left ventricular (LV) ejection fraction (=45%), including: n = 129 with HFPEF, n = 158 with HHD and no heart failure, and n = 40 normotensive controls. From detailed measurements of LV systolic strain performed in multiple views, we derived and then compared regional measures of basal, mid-ventricular, and apical longitudinal strains. In models adjusting for clinical covariates, basal and mid-ventricular LV myocardial deformation was more impaired in HHD than in controls (P = 0.003), whereas apical deformation was more impaired in HFPEF than in HHD (P = 0.005). In multivariable-adjusted analyses, only apical strain remained independently associated with HFPEF vs. HHD status [odds ratio 1.18 (1.02-1.37), P = 0.030 per 1% decrease in apical strain]. Compared to other regional strains, apical longitudinal strain optimally differentiated HFPEF from HHD (area under the receiver operating curve: apical longitudinal strain = 0.67; mid-ventricular longitudinal strain = 0.59; basal longitudinal strain = 0.60).Conclusion We found that while apical mechanical function is preserved in HHD, it was impaired in HFPEF and may contribute to the transition from an asymptomatic heart disease to a symptomatic heart disease.

Published
2023

21. Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction

Author

Biering-Sørensen, Tor, primary, Cikes, Maja, additional, Lassen, Mats C H, additional, Claggett, Brian, additional, Minamisawa, Masatoshi, additional, Santos, Angela B S, additional, Pieske-Kraigher, Elisabeth, additional, Shah, Amil M, additional, Zile, Michael R, additional, McMurray, John J V, additional, Solomon, Scott D, additional, and Cheng, Susan, additional

Published
2023
Full Text
View/download PDF

25. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with prior heart failure undergoing percutaneous coronary intervention: sub-analysis of the SHINANO registry

Author

Minamisawa, Masatoshi, Miura, Takashi, Motoki, Hirohiko, Kobayashi, Hideki, Kobayashi, Masanori, Nakajima, Hiroyuki, Kimura, Hikaru, Akanuma, Hiroshi, Mawatari, Eiichiro, Sato, Toshio, Hotta, Shoji, Kamiyoshi, Yuichi, Maruyama, Takuya, Watanabe, Noboru, Eisawa, Takayuki, Aso, Shinichi, Uchikawa, Shinichiro, Senda, Keisuke, Morita, Takehiro, Hashizume, Naoto, Abe, Naoyuki, Ebisawa, Soichiro, Izawa, Atsushi, Miyashita, Yusuke, Koyama, Jun, Ikeda, Uichi, and On behalf of the SHINANO Registry Investigators

Published
2017
Full Text
View/download PDF

26. Prognostic value of ankle brachial index for future incident heart failure in patients without previous heart failure: data from the impressive predictive value of ankle brachial index for clinical long term outcome in patients with cardiovascular disease examined by ABI study

Author

Nishimura, Hitoshi, Miura, Takashi, Minamisawa, Masatoshi, Ueki, Yasushi, Abe, Naoyuki, Hashizume, Naoto, Mochidome, Tomoaki, Harada, Mikiko, Shimizu, Kunihiko, Shoin, Wataru, Yoshie, Koji, Oguchi, Yasutaka, Ebisawa, Soichiro, Motoki, Hirohiko, Izawa, Atsushi, Koyama, Jun, and Ikeda, Uichi

Published
2017
Full Text
View/download PDF

29. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction

Author

Davies, Daniel R., primary, Redfield, Margaret M., additional, Scott, Christopher G., additional, Minamisawa, Masatoshi, additional, Grogan, Martha, additional, Dispenzieri, Angela, additional, Chareonthaitawee, Panithaya, additional, Shah, Amil M., additional, Shah, Sanjiv J., additional, Wehbe, Ramsey M., additional, Solomon, Scott D., additional, Reddy, Yogesh N. V., additional, Borlaug, Barry A., additional, and AbouEzzeddine, Omar F., additional

Published
2022
Full Text
View/download PDF

30. Abstract 17741: Prognostic Value of Ankle-Brachial Index for Future Amputation and Critical Limb Ischemia in Patients With Peripheral Artery Disease

Author

Nomi, Hidetomo, Nishimura, Hitoshi, Miura, Takashi, Minamisawa, Masatoshi, Ueki, Yasushi, Abe, Naoyuki, Hashizume, Naoto, Mochidome, Tomoaki, Harada, Mikiko, Shimizu, Kunihiro, Shoin, Wataru, Yoshie, Koji, Oguchi, Yasutaka, Saigusa, Tatsuya, Ebisawa, Soichiro, Motoki, Hirohiko, Izawa, Atsushi, Koyama, Jun, Ikeda, Uichi, and Kuwahara, Koichiro

Published
2017

33. Association of Left Atrial Structure and Function With Heart Failure in Older Adults

Author

Inciardi, Riccardo M., primary, Claggett, Brian, additional, Minamisawa, Masatoshi, additional, Shin, Sung-Hee, additional, Selvaraj, Senthil, additional, Gonçalves, Alexandra, additional, Wang, Wendy, additional, Kitzman, Dalane, additional, Matsushita, Kunihiro, additional, Prasad, Narayana G., additional, Su, Jimmy, additional, Skali, Hicham, additional, Shah, Amil M., additional, Chen, Lin Yee, additional, and Solomon, Scott D., additional

Published
2022
Full Text
View/download PDF

34. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial

Author

Suzuki, Kota, Claggett, Brian, Minamisawa, Masatoshi, Packer, Milton, Zile, Michael R., Pfeffer, Marc A., Chiang, Lu‐May, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., and Desai, Akshay S.

Abstract

Aims: \ud The 4822 patients randomized in the PARAGON-HF trial were a subset of 5746 initially eligible patients who entered sequential run-in periods. We identified patient factors associated with study discontinuation during the run-in period and estimated the implications of these discontinuations for the overall study result.\ud \ud Methods and Results: \ud We utilized multivariable logistic regression models to identify patient factors associated with study discontinuation during the run-in. The efficacy of sacubitril/valsartan in a broader cohort approximating the full run-in population was estimated by weighting randomized patients according to the inverse probability of run-in completion. A total of 924 (16.1%) subjects failed to complete the run-in period. In multivariable models, noncompletion was associated with region other than Central Europe, lower systolic blood pressure, lower serum sodium, lower hemoglobin, lower estimated glomerular filtration rate, higher NT-proBNP, higher NYHA functional class, prior HF hospitalization, and lack of prior use of renin-angiotensin system inhibitors or beta-blocker. In repeat analysis of the effect of randomized treatment in PARAGON-HF giving greater weight to participants resembling those who failed to complete the run-in period, the incidence of HF hospitalizations and cardiovascular death was higher, and sacubitril/valsartan treatment reduced the composite of total HF hospitalizations and cardiovascular death compared with valsartan (rate ratio, 0.86; 95% confidence interval, 0.74–1.00).\ud \ud Conclusion: \ud Patients with more advanced heart failure were at higher risk for noncompletion of the run-in period in PARAGON-HF. Reanalysis of study outcomes accounting for the effect of run-in noncompletion did not alter the estimated treatment effects of sacubitril/valsartan vs valsartan.

Published
2021

36. Effect of patisiran on stroke volume in hereditary transthyretin‐mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study.

Author

Rosenblum, Hannah R., Griffin, Jan M., Minamisawa, Masatoshi, Prasad, Narayana, Vest, John, White, Matthew T., Solomon, Scott D., Burkhoff, Daniel, and Maurer, Mathew S.

Subjects
RNA interference, AMYLOIDOSIS, CLINICAL trials, TRANSTHYRETIN
Abstract

Aims: Transthyretin‐mediated (ATTR) amyloidosis is caused by deposition of transthyretin protein fibrils in the heart, nerves, and other organs. Patisiran, an RNA interference therapeutic that inhibits hepatic synthesis of transthyretin, was approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy based on the phase 3 APOLLO study. We use left ventricular (LV) stroke volume (SV) to quantify LV function overtime and non‐invasive pressure–volume techniques to delineate the effects of patisiran on LV mechanics in the pre‐specified cardiac subpopulation of the APOLLO study. Methods and results: Left ventricular SV was assessed by transthoracic echocardiography at baseline, and after 9 and 18 months of therapy. To determine the mechanisms underlying changes in LV SV, non‐invasive pressure–volume parameters, including the end‐systolic and end‐diastolic pressure–volume relationship, were derived using single beat techniques. At baseline, the mean SV was 51 ± 14 ml. At 9 months, the least‐squares mean change in SV was −0.3 ± 1.2 ml for patisiran and −5.4 ± 1.9 ml for placebo (p = 0.021). At 18 months, the least‐squares mean change in SV was −1.7 ± 1.3 ml for patisiran and − 8.1 ± 2.3 ml for placebo (p = 0.016). Decline in LV SV was driven by diminished LV capacitance in placebo relative to patisiran. Conclusions: Patisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin‐reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase 3 trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF

Author

Mooney, Leanne, primary, Hawkins, Nathaniel M., additional, Jhund, Pardeep S., additional, Redfield, Margaret M., additional, Vaduganathan, Muthiah, additional, Desai, Akshay S., additional, Rouleau, Jean L., additional, Minamisawa, Masatoshi, additional, Shah, Amil M., additional, Lefkowitz, Martin P., additional, Zile, Michael R., additional, Van Veldhuisen, Dirk J., additional, Pfeffer, Marc A., additional, Anand, Inder S., additional, Maggioni, Aldo P., additional, Senni, Michele, additional, Claggett, Brian L., additional, Solomon, Scott D., additional, and McMurray, John J. V., additional

Published
2021
Full Text
View/download PDF

38. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction

Author

Minamisawa, Masatoshi, primary, Claggett, Brian, additional, Suzuki, Kota, additional, Hegde, Sheila M., additional, Shah, Amil M., additional, Desai, Akshay S., additional, Lewis, Eldrin F., additional, Shah, Sanjiv J., additional, Sweitzer, Nancy K., additional, Fang, James C., additional, Anand, Inder S., additional, O’Meara, Eileen, additional, Rouleau, Jean-Lucien, additional, Pitt, Bertram, additional, Pfeffer, Marc A., additional, Solomon, Scott D., additional, and Vardeny, Orly, additional

Published
2021
Full Text
View/download PDF

40. Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans

Author

Minamisawa, Masatoshi, primary, Inciardi, Riccardo M., additional, Claggett, Brian, additional, Cuddy, Sarah A.M., additional, Quarta, Candida C., additional, Shah, Amil M., additional, Dorbala, Sharmila, additional, Falk, Rodney H., additional, Matsushita, Kunihiro, additional, Kitzman, Dalane W., additional, Chen, Lin Y., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

41. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)

Author

Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., Solomon, Scott D., Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., and Solomon, Scott D.

Published
2021

43. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )

Author

Biering‐Sørensen, Tor, primary, Minamisawa, Masatoshi, additional, Liu, Jiankang, additional, Claggett, Brian, additional, Papolos, Alexander I., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, Teerlink, John R., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

45. RELATIVE APICAL SPARING PATTERN IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (THE PARAGON-HF AND TOPCAT TRIALS)

Author

Minamisawa, Masatoshi, primary, Cuddy, Sarah, additional, Claggett, Brian, additional, Cikes, Maja, additional, Redfield, Margaret, additional, Shah, Sanjiv, additional, Garcia-Pavia, Pablo, additional, Zile, Michael, additional, Rouleau, Jean, additional, Packer, Milton, additional, Pfeffer, Marc, additional, McMurray, John, additional, Shah, Amil, additional, and Solomon, Scott, additional

Published
2021
Full Text
View/download PDF

47. A SIMPLE SCORE TO PREDICT TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

Author

Davies, Daniel, primary, Minamisawa, Masatoshi, additional, Scott, Christopher, additional, Grogan, Martha, additional, Dispenzieri, Angela, additional, Chareonthaitawee, Panithaya, additional, Shah, Amil, additional, Shah, Sanjiv, additional, Solomon, Scott, additional, Redfield, Margaret, additional, and AbouEzzeddine, Omar, additional

Published
2021
Full Text
View/download PDF

48. Cardio-renal and cardio-hepatic interactions predict cardiovascular events in elderly patients with heart failure

Author

Okano, Takahiro, primary, Motoki, Hirohiko, additional, Minamisawa, Masatoshi, additional, Kimura, Kazuhiro, additional, Kanai, Masafumi, additional, Yoshie, Koji, additional, Higuchi, Satoko, additional, Saigusa, Tatsuya, additional, Ebisawa, Soichiro, additional, Okada, Ayako, additional, Shoda, Morio, additional, and Kuwahara, Koichiro, additional

Published
2020
Full Text
View/download PDF

49. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction

Author

Suzuki, Kota, primary, Claggett, Brian, additional, Minamisawa, Masatoshi, additional, Packer, Milton, additional, Zile, Michael R., additional, Rouleau, Jean, additional, Swedberg, Karl, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, McMurray, John J.V., additional, Zucker, Stephen D., additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

50. LEFT ATRIAL STRUCTURE AND FUNCTION OF THE AMYLOIDOGENIC V122I TRANSTHYRETIN VARIANT IN ELDERLY AFRICAN AMERICANS

Author

Minamisawa, Masatoshi, primary, Inciardi, Riccardo M., additional, Claggett, Brian, additional, Cuddy, Sarah, additional, Quarta, Candida Cristina, additional, Shah, Amil, additional, Dorbala, Sharmila, additional, Falk, Rodney, additional, Matsushita, Kunihiro, additional, Kitzman, Dalane W., additional, Chen, Lin Yee, additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results